This insider selling cluster is too small to carry a directional signal. Both sales occurred on the same day at the same price, suggesting potentially coordinated or routine liquidity-driven dispositions. No follow-up monitoring needed unless larger non-10b5-1 sales emerge.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 10 $6.98entry
- T+1 · 4mo ago +0.43%α +1.20% · $7.01
- T+5 · 4mo ago +0.57%α +1.13% · $7.02
- T+20 · 3mo ago +3.72%α +1.30% · $7.24
- T+60 · 6w ago −26.79%α −29.42% · $5.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Abeona Therapeutics (ABEO), the Chief Commercial Officer and SVP/Chief Legal Officer, conducted open-market sales totaling approximately $172K on July 9, 2026. The combined value represents less than 0.05% of the company's $388M market cap, making the cluster economically trivial and consistent with routine portfolio management rather than a bearish signal.
Key Financial Metrics
Key Facts
- Two insiders sold shares on 2026-07-09: CCO Madhav Vasanthavada (12,606 shares, ~$88K) and SVP/CLO Brendan M. O'Malley (12,050 shares, ~$84K)
- Total proceeds: approximately $172K
- Combined sales represent ~0.044% of ABEO's $388M market capitalization
- No open-market purchases were reported in the same window
Financial Impact
Insignificant relative to market cap, total sales under $200K
Risk Factors
- If insiders accelerate selling in future clusters without a 10b5-1 plan, that could signal growing bearish conviction
- ABEO's small market cap means even modest insider selling can appear proportionally larger, but this cluster remains within noise levels
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABEO-1783639232065 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers